Order the test
Ask your physician if you are eligible for the prime DX test.
Sample requirement
Tissue from surgery or biopsy which is embedded in paraffin (FFPET) or liquid biopsy (Plasma) is required for this test. Your sample will be collected per your physician’s' instructions.
Analysis Process
Your sample will arrive to our accredited laboratory and your report will be generated and released to you and your physician in 15 working days.
Reporting
Your report will be electronically released to your physician via email and/or uploaded to our secure portal, and to you via email or mail.
prime DX - molecular test
This breakthrough technology along with cloud computing and bioinformatics work together in order to analyze massive volumes of data from the patients’ genome and transform it into an interactive report providing information on these main categories of results:
- Molecular profiling of the tumor tissue with details on specific gene mutations.
- Suggested on-label Therapies that can be of great benefit to the specific patient with interactive feed of medical information
- Suggested off-label therapies that can be of great benefit to the specific patient with interactive feed of medical information
- Suggested investigational therapies with interactive feed of clinical trials .
- Treatments with associated resistance- that will not be of benefit to the specific patient.
- Medication suggestions with recorded indications.
prime DX® Liquid
The new prime DX® Liquid test consists of a panel of 1021 genes, which analyses the immunotherapy biomarkers TMB, MSI, HLA, allowing the treating physician to plan an effective treatment for the patient, including immunotherapy, chemotherapy, PARP inhibitors and compatibility of participation in clinical trials.
Additionally, prime DX® Liquid, analyses genes involved in genetic predisposition to cancer, thus providing information to the physician about the likelihood of an inherited cancer syndrome.
Recommended for the following cases:
- When there is not enough tissue or recent biopsy
- If the tissue quality is poor (e.g. too much bone in the sample)
- When there is a metastatic and multifocal disease
- After treatment to check patient’s response
- If the patient relapses and there is a need for molecular profiling without biopsy
![]()
prime DX® Combo
The prime DX® Combo enables the simultaneous analysis of FFPE tissue samples and liquid biopsy, offering a comprehensive molecular profile that combines the benefits of both methods.
Why choose a combined tissue and liquid biopsy analysis?
The combination of these two approaches allows clinicians to gain a more holistic view of a patient’s tumor biology, facilitating more informed treatment decisions. Parallel analysis offers:
- Faster response time, ensuring that patients receive appropriate treatment promptly.
- Greater diagnostic accuracy, thanks to enhanced sensitivity in mutation detection, reducing false-negative results.
![]()
Prime DX is a 1021-gene NGS panel, where 36 of these are HR genes.
The test also includes:
| Immunotherapy Biomarkers | PARP Inhibitors Biomarkers | IHC Biomarkers |
| TMB | LOH | PD-L1 |
| MSI | HER-2 | |
| HLA | FRα | |
| CLDN18.2 |
Agnostic Markers
| Targeted Therapies | Immunotherapies |
| NTRK1,2,3 | TMB |
| RET Fusions | MSI |
| BRAFV600E Mutation | |
| HER2 Amplification |
It is one of the most detailed, sensitive and specific tests for tumor biology configuration, enabling physicians to plan an efficient treatment strategy for the patient, including immunotherapy, chemotherapy, PARP inhibitors and clinical trial participation compatibility.
Why choose prime DX?
- prime DX analyzes 1021 genes associated with cancer syndromes and additionally the immunotherapy biomarkers HLA, MSI, PD-L1, TMB and LOH, giving the physician a clear picture of which treatments will benefit the patient and which will not, including immunotherapy, chemotherapy and of PARP inhibitors
- Continuous support to the doctor and the patient from our experienced team
- The report incorporates interactive links, which redirect the physician to medical information about the specific gene mutation and other relevant medical data
- Analyzing several genes simultaneously with the use of a small sample of tissue of tissue or liquid biopsy (Plasma) at a low cost
- State of the art technology, which has demonstrated high reproducibility, sensitivity and specificity
Results & Reporting
Who should be tested?
prime DX Molecular Cancer Test
prime DX is designed in order to allow you and your physician to select which is the optimal targeted treatment based on your unique tumor biology.
This test is designed for the following cases:
- Aggressive tumors with no standard treatment
- When the initial treatment plan has been completed but more treatment options must be taken under consideration.
- Second line treatment
- Tumors with many available treatment options where the physician must clarify which one will be the most effective on a particular patient.
- For a clear indication of the patient’s response for the physician to know if a treatment plan would be appropriate and/or in order to create the most effective treatment plan.
- Tumors of unknown primary tumor
- Rare tumors.
- Tumors without an established “gold standard” treatment
